Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)

NCT01518387 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01518387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01518387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
July 31, 2006
Enrollment
43 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia